Hello, and welcome to Acumen Pharmaceuticals Q3 2024 conference call and webcast. At this time, all participants are in a listen-only mode. As of the speaker's presentation, there will be a ...

The positive rate of amyloid beta protein, indicating the risk of Alzheimer's disease-causing substance accumulation, was ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic ...

NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble ...

Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

In a major discovery, scientists have presented the first evidence of Alzheimer's disease transmission in living individuals.

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Leqembi’s sales continue to be underwhelming, according to analysts, who contend the companies’ Alzheimer’s disease therapy ...

But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and ...

Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.

Cassava Sciences, Inc. ( NASDAQ: SAVA) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Rick Barry - President & Chief Executive Officer Eric Schoen - Chief Financial Officer ...